Evolus (NASDAQ:EOLS) Issues Earnings Results, Misses Estimates By $0.09 EPS

Evolus (NASDAQ:EOLS) issued its earnings results on Tuesday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.09), Zacks reports. Evolus had a negative return on equity of 847.60% and a negative net margin of 22.33%.

Evolus Stock Performance

Shares of EOLS stock traded up $0.01 during trading hours on Tuesday, reaching $14.35. 899,628 shares of the company traded hands, compared to its average volume of 593,467. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82. The firm has a 50-day moving average price of $12.72 and a 200 day moving average price of $14.08. The company has a market cap of $908.66 million, a P/E ratio of -15.77 and a beta of 1.33.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Tuesday, January 21st. Barclays increased their price objective on shares of Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Friday, February 14th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.